Public procurement notice: Modification Of A Contract/Concession During Its Term
Published: 2019-11-06
Buyer: NHS Blood and Transplant
Country: UK
Contract type: Supplies
CPV classification: 33140000: Medical consumables | 33621400 | 33692400

Technical requirements: NHS Blood and Transplant (the Authority) is the commissioner responsible for providing funding, infrastructure, clinical guidance and standards to the National Organ Retrieval Service (NORS). NORS is comprised of several organ retrieval teams (Teams) based at a range of transplant centres in England, Wales and Scotland. The Authority has a contract in place with each NORS team, for the provision of organ retrieval services. The Teams purchase their own consumables and are reimbursed each financial quarter by the Authority.
According to the recent developments a new tender perfusion fluid solution is now due to be issued in late November 2019.
Due to the delay in the tender being issued NHSBT agreed with all current suppliers and potential bidders (as identified via the PIN 2019/S 040-089561) that the current supply of of Lot 1 (Bridge to Life Ltd) in NHSBT0666 to extend this existing agreement beyond 1.11.2019 by 8 months (to 1.7.2020).
Due to commercially sensitive issues, NHSBT agreed with all current suppliers and potential bidders (as identified via the PIN 2019/S 040-089561) that the current supply of of Lot 2 (Baxter and Pharmapal) in NHSBT0666 to extend this existing agreement beyond 1.11.2019 by 12 months (to 1.11.2020).
NHS Blood and Transplant (the Authority) is the commissioner responsible for providing funding, infrastructure, clinical guidance and standards to the National Organ Retrieval Service (NORS). NORS is comprised of several organ retrieval teams (Teams) based at a range of transplant centres in England, Wales and Scotland. The Authority has a contract in place with each NORS team, for the provision of organ retrieval services. The Teams purchase their own consumables and are reimbursed each financial quarter by the Authority.
According to the recent developments a new tender perfusion fluid solution is now due to be issued in late November 2019.
Due to the delay in the tender being issued NHSBT agreed with all current suppliers and potential bidders (as identified via the PIN 2019/S 040-089561) that the current supply of of Lot 1 (Bridge to Life Ltd) in NHSBT0666 to extend this existing agreement beyond 1.11.2019 by 8 months (to 1.7.2020).
Due to commercially sensitive issues, NHSBT agreed with all current suppliers and potential bidders (as identified via the PIN 2019/S 040-089561) that the current supply of of Lot 2 (Baxter and Pharmapal) in NHSBT0666 to extend this existing agreement beyond 1.11.2019 by 12 months (to 1.11.2020).
Total value of increase in price does not exceed 50 % of the value of the original framework agreement; The nature of contract has not been changed.
Commercially sensitive issues; total value of increase in price does not exceed 50 % of the value of the original framework agreement; The nature of contract has not been changed.
According to the recent developments a new tender perfusion fluid solution is now due to be issued in late November 2019.
Due to the delay in the tender being issued NHSBT agreed with all current suppliers and potential bidders (as identified via the PIN 2019/S 040-089561) that the current supply of of Lot 1 (Bridge to Life Ltd) in NHSBT0666 to extend this existing agreement beyond 1.11.2019 by 8 months (to 1.7.2020).
Due to commercially sensitive issues, NHSBT agreed with all current suppliers and potential bidders (as identified via the PIN 2019/S 040-089561) that the current supply of of Lot 2 (Baxter and Pharmapal) in NHSBT0666 to extend this existing agreement beyond 1.11.2019 by 12 months (to 1.11.2020).
Total value of increase in price does not exceed 50 % of the value of the original framework agreement; The nature of contract has not been changed.
A change of supplier would not be practicable (for economic reasons) and would involve substantial inconvenience and duplication of costs (limited to 50 % of original contract price). Total value of increase in price does not exceed 50 % of the value of the original framework agreement.


Winner: Baxter Healthcare Ltd